Confo Therapeutics
Michael Devos holds a Ph.D. in Biotechnology from Ghent University. Michael has worked as a Postdoctoral Researcher at VIB with a focus on skin biology, immunity, cancer, and cell death. Michael also served as a biology teacher at KA Geraardsbergen and as a Doctor Assistant at UGent. Currently, at Confo Therapeutics, Michael has held roles as Scientist in the Biology team and is now the Senior Scientist and Team Lead. Prior to their current position, Michael spent a year traveling in Australia and Asia.
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.